In addition, KEYNOTE-059 findings indicated that patients with MSI-H gastric cancer achieved markedly higher objective response rates than non–MSI-H counterparts following PD-1 inhibitor therapy (57.1% vs 9%) [9]. This evidence concerns the gene PDCD1 and gastric cancer.